Cybin Inc. Common Stock

Cybin (recently rebranded to Helus Pharma) is a clinical-stage psychedelic-therapy biotech — HLP003 (formerly CBIN-004) is the lead program targeting major depressive disorder as an adjunctive treatment, and the Phase 3 APPROACH study enrollment recently completed. The equity is essentially a September pivotal-readout binary.

• The September readout is the whole binary: Phase 3 APPROACH enrollment is complete and the treatment protocol is just two doses spaced 21 days apart — that's the specific dosing regimen that if it hits the primary endpoint (MADRS depression scale improvement), unlocks a genuinely differentiated treatment for a large TAM population, and could compare favorably to Compass Pathways' Phase 2 data.
• The financial state is standard clinical biotech: zero revenue against a $32M quarterly cash burn, consensus FY26 EPS of -$4.03 — the $720M market cap prices near-zero probability of failure but full commercial credit for approval on a probability-weighted basis, which is standard for the archetype.
• The comparative framing bulls anchor on: HELP has roughly 2x better MADRS efficacy than DFTX Phase 2 data (posters flag), and the CEO's M&A track record adds strategic-value optionality — plus the recent name change to Helus Pharma and the CEO appointment position the company for a commercial launch stance if the readout lands.

What resolves the event upward is positive Phase 3 APPROACH data on the primary endpoint (MADRS depression-scale improvement); what breaks it down is a primary-endpoint miss or a safety-signal disclosure that reveals the differentiated dosing regimen doesn't translate to durable efficacy — this is a binary equity event.